Skip to content
Research Article Open access CC BY 4.0

A New Fixed Dose Combination of Ceftriaxone + Sulbactam + Disodium Edetate for Definitive Treatment of Infections Due to Piperacillin/ Tazobactam Resistant Bacteria: A Retrospective Efficacy and Pharmacoeconomic Study

Prashant Bhatia, Mohd Amin Mir

Journal of Advances in Medicine and Medical Research · pp. 1–14 · Published 25 Apr 2016

10.9734/BJMMR/2016/25102

Abstract

Objective: Present retrospective study was aimed to analyze comparative efficacy of fixed dose combination (FDC) (ceftriaxone + sulbactam + disodium edetate) and meropenem used alone or in combinations with other antibiotics for management of intensive care unit (ICU) patients suffering with infections from piperacillin-tazobactam (pip-taz) resistant bacteria and to assess the costs associated with respective therapies. Methodology: Patients records were collected and their demographic characteristics, infection types, co-morbidities, antibiotic therapy, dosage, treatment duration microbial and clinical success rates were evaluated. Effectiveness and costs analysis between antibiotic regimens were estimated in Indian rupees (INR). A total of 136 patients data treated at a tertiary-care hospital was analyzed. These 136 patients included 28, 18, 19, 17, 31 and 23 patients of urinary tract infection (UTI), blood stream infection (BSI), community acquired infection (CAI), skin structure infection (SSI), intra-abdominal infection (IAI) and ventilator associated pneumonia (VAP), respectively. Out of 136 patients, 56 patients received FDC and another 80 patients were administered with meropenem empirically. Results: Clinical cure observed was 71.42% and 67.50% in FDC and meropenem groups, respectively. The patients in whom meropenem and FDC treatment regime failed to show improvement, colistin was given as an additional cover, which resulted in clinical cure of 86.95% and 85.71% patients respectively. Comparative cost expenditure analysis of these two drug treatment regimens revealed that, the overall treatment cost for patients cured with antibiotic regimen containing meropenem was 107.39% more than that of FDC. The strongest contributors of the increase in treatment costs were cost of antibiotic, number of dosages, average treatment duration and clinical failure rates. Conclusion: Infections with pip-taz resistant bacteria are frequent in ICU patients and the present study demonstrates that FDC has comparatively similar efficacy as that of meropenem which is considered as an appropriate option to treat pip-taz resistant cases. Pharmacoeconomic analysis clearly advocates in favor of FDC as a cheaper and safer alternative to meropenem to treat ICU patients with infections caused due to pip-taz resistant bacteria.

Piperacillin/tazobactam fixed dose combination intensive care units pharmacoeconomic multi-drug resistant bacteria

References (40)

  1. 1 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer [DOI]
  2. 2 Novel Carbapenem-Hydrolyzing β-Lactamase, KPC-1, from a Carbapenem-Resistant Strain of Klebsiella pneumoniae [DOI]
  3. 3 Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America [DOI]
  4. 4 Impact of BAL Data on the Therapy and Outcome of Ventilator-Associated Pneumonia [DOI]
  5. 5 Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies [DOI]
  6. 6 Transferable imipenem resistance in Pseudomonas aeruginosa [DOI]
  7. 7 Rapid Spread of Carbapenem-Resistant Klebsiella pneumoniae in New York City [DOI]
  8. 8 Guidelines for the Selection of Anti-infective Agents for Complicated Intra-abdominal Infections [DOI]
  9. 9 Predictors of Carbapenem-Resistant Klebsiella pneumoniae Acquisition among Hospitalized Adults and Effect of Acquisition on Mortality [DOI]
  10. 10 Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae : Importance of Inadequate Initial Antimicrobial Treatment [DOI]
  11. 11 Klebsiella pneumoniae AcrAB Efflux Pump Contributes to Antimicrobial Resistance and Virulence [DOI]
  12. 12 2013 WSES guidelines for management of intra-abdominal infections [DOI]
  13. 13 Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosa [DOI]
  14. 14 Discovery research: the scientific challenge of finding new antibiotics [DOI]
  15. 15 Combination Therapy with Intravenous Colistin for Management of Infections Due to Multidrug-Resistant Gram-Negative Bacteria in Patients without Cystic Fibrosis [DOI]
  16. 16 Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial [DOI]
  17. 17 Newer antibacterial drugs for a new century [DOI]
  18. 18 Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, India [DOI]
  19. 19 AcrB Multidrug Efflux Pump of Escherichia coli : Composite Substrate-Binding Cavity of Exceptional Flexibility Generates Its Extremely Wide Substrate Specificity [DOI]
  20. 20 Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery [DOI]
  21. 21 Trends in Antimicrobial Resistance in Health Care–Associated Pathogens and Effect on Treatment [DOI]
  22. 22 Randomized Controlled Trial of Moxifloxacin Compared With Piperacillin???Tazobactam and Amoxicillin???Clavulanate for the Treatment of Complicated Intra-abdominal Infections [DOI]
  23. 23 Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults [DOI]
  24. 24 Inappropriate initial treatment of secondary intra‐abdominal infections leads to increased risk of clinical failure and costs [DOI]
  25. 25 Cost of Care for Inpatients with Community-Acquired Intra-Abdominal Infections [DOI]
  26. 26 Daily serum piperacillin monitoring is advisable in critically ill patients [DOI]
  27. 27 Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009 [DOI]
  28. 28 Overcoming drug resistance in multi-drug resistant cancers and microorganisms [DOI]
  29. 29 Spread of IS CR1 Elements Containing bla DHA-1 and Multiple Antimicrobial Resistance Genes Leading to Increase of Flomoxef Resistance in Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae [DOI]
  30. 30 A Novel Approach to Combat Acquired Multiple Resistance in Escherichia coli by using EDTA as Efflux Pump Inhibitor [DOI]
  31. 31 Prevalence of Staphylococcus aureus introduced into intensive care units of a University Hospital [DOI]
  32. 32 First Identification and Characterization of an AdeABC-Like Efflux Pump in Acinetobacter Genomospecies 13TU [DOI]
  33. 33 Cost of care and antibiotic prescribing attitudes for community-acquired complicated intra-abdominal infections in Italy: a retrospective study [DOI]
  34. 34 Role of CSE1034 in Escherichia coli Biofilm Destruction [DOI]
  35. 35 Characterization of Extended-Spectrum Beta-Lactamases and qnr Plasmid-Mediated Quinolone Resistance in German Isolates of Enterobacter Species [DOI]
  36. 36 Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: A retrospective study [DOI]
  37. 37 Sulbactomax prevents antimicrobial resistance development byinhibition of conjugal transfer of F plasmids
  38. 38 Does Initial Choice of Antimicrobial Therapy Affect Length of Stay for Patients with Complicated Intra-abdominal Infections? [DOI]
  39. 39 Analysis of Enterobacteriaceae Producing Broad-Spectrum Beta-Lactamases in the Intensive Care Unit Setting [DOI]
  40. 40 Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee.

Cited by 2

Advancing in the Direction of Right Solutions: Treating Multidrug-Resistant Pneumonia

Manu Chaudhary, Gazalla Ayub, Anurag Payasi · Contemporary Topics of Pneumonia · 2017

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Article metrics

Real usage data collected on this platform.

34

Page views

0

PDF downloads

4

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.